ES2075199T3 - Glicoproteina de origen humano; factor activo fisiologicamente que comprende la misma, y preparacion farmaceutica que contiene la misma como ingrediente activo. - Google Patents

Glicoproteina de origen humano; factor activo fisiologicamente que comprende la misma, y preparacion farmaceutica que contiene la misma como ingrediente activo.

Info

Publication number
ES2075199T3
ES2075199T3 ES90904429T ES90904429T ES2075199T3 ES 2075199 T3 ES2075199 T3 ES 2075199T3 ES 90904429 T ES90904429 T ES 90904429T ES 90904429 T ES90904429 T ES 90904429T ES 2075199 T3 ES2075199 T3 ES 2075199T3
Authority
ES
Spain
Prior art keywords
same
glycoprotein
human origin
pharmaceutical preparation
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904429T
Other languages
English (en)
Inventor
Kanji Higashio
Shinjiro Mitsuda
Nobuyuki Shima
Yasuharu Itagaki
Masaya Nagao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26340889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2075199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Application granted granted Critical
Publication of ES2075199T3 publication Critical patent/ES2075199T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE OBTIENE UNA GLICOPROTEINA DESDE UN SUPERNATANTE DE UN MEDIO DE CULTIVO DE LOS FIBROBLASTOS DE ORIGEN HUMANO. TIENE ACTIVIDAD ANTITUMOROSA Y ACTIVIDADES DE INDUCIR LA DIFERENCIACION DE CELULAS DE LEUCEMIA, INMUNIDAD REALZADA DE MEDIACION DE CELULAS, ACELERAR LA PROLIFERACION DE CELULAS ENDOTELIALES DE VASOS SANGUINEOS HUMANOS Y PROLIFERAR CELULAS PARENCIMALES HEPATICAS.
ES90904429T 1989-03-10 1990-03-09 Glicoproteina de origen humano; factor activo fisiologicamente que comprende la misma, y preparacion farmaceutica que contiene la misma como ingrediente activo. Expired - Lifetime ES2075199T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5863189 1989-03-10
JP669290 1990-01-16

Publications (1)

Publication Number Publication Date
ES2075199T3 true ES2075199T3 (es) 1995-10-01

Family

ID=26340889

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90904429T Expired - Lifetime ES2075199T3 (es) 1989-03-10 1990-03-09 Glicoproteina de origen humano; factor activo fisiologicamente que comprende la misma, y preparacion farmaceutica que contiene la misma como ingrediente activo.

Country Status (17)

Country Link
US (2) US5587359A (es)
EP (1) EP0462277B1 (es)
JP (1) JPH0768272B2 (es)
KR (1) KR960009054B1 (es)
AT (1) ATE123498T1 (es)
AU (1) AU629314B2 (es)
CA (1) CA2049017C (es)
DE (1) DE69019962T2 (es)
DK (1) DK0462277T3 (es)
ES (1) ES2075199T3 (es)
FI (1) FI102681B (es)
HU (2) HU212513B (es)
IE (1) IE64005B1 (es)
NO (1) NO180796C (es)
NZ (1) NZ232813A (es)
RU (1) RU2113480C1 (es)
WO (1) WO1990010651A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
DE69133492T2 (de) * 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
EP0539590B1 (en) * 1990-07-13 1999-03-31 Snow Brand Milk Products Co., Ltd. Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same
US5821223A (en) * 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
DE69133349T2 (de) * 1990-09-14 2004-10-07 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
JPH0597A (ja) * 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法
JP3380573B2 (ja) 1992-07-16 2003-02-24 第一製薬株式会社 Ｔｃｆ−ｉｉを有効成分とする蛋白合成促進剤
ES2276409T3 (es) 1992-07-16 2007-06-16 Daiichi Pharmaceutical Co., Ltd. Composicion medica que contiene tcf-ii.
EP0653211B1 (en) * 1992-07-16 2001-10-17 Snow Brand Milk Products Co., Ltd. Blood coagulation normalizer containing tcf-ii as active ingredient
US5648233A (en) * 1992-12-28 1997-07-15 Snow Brand Milk Products Co., Ltd. Modified tumor cytotoxic factor (TCF) and DNA encoding such
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
NZ298141A (en) * 1994-12-27 2000-12-22 Snow Brand Milk Products Co Ltd Treating lipid metabolism disorder using TCF-II
DE69531673T2 (de) * 1994-12-27 2004-07-08 Daiichi Pharmaceutical Co., Ltd. Tcf mutante
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU4027601A (en) * 1995-07-11 2001-07-26 Snow Brand Milk Products Co., Ltd. Lyophilized HGF preparations
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
AU734766B2 (en) * 1997-03-14 2001-06-21 Atlas Pharmaceuticals Inc. Agent for preventing and/or treating cachexia
JPH1129493A (ja) * 1997-07-14 1999-02-02 Snow Brand Milk Prod Co Ltd 放射線障害予防及び／又は治療剤
JPH11269091A (ja) * 1998-03-19 1999-10-05 Snow Brand Milk Prod Co Ltd 敗血症予防及び／又は治療剤
CN1352087A (zh) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人糖蛋白42和编码这种多肽的多核苷酸
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CN100417412C (zh) * 2003-03-28 2008-09-10 威海赛洛金药业有限公司 促肝细胞生长素注射液及制备方法和应用
EP1661578B1 (en) * 2003-09-03 2018-03-14 Toshikazu Nakamura Skin ulcer preventive curative agent containing human recombinant hgf
WO2007085626A1 (en) * 2006-01-25 2007-08-02 Octapharma Ag Purification and use of a factor for supporting wound healing
JP4347408B2 (ja) * 2007-04-28 2009-10-21 株式会社エーシーバイオテクノロジーズ 皮膚または歯肉の軟組織の欠損を補修するための組成物，及び自己線維芽細胞の培養方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
KR101290322B1 (ko) * 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제
CN105682676B (zh) 2013-10-22 2020-10-23 赫利世弥斯株式会社 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物
US11547743B2 (en) * 2014-04-28 2023-01-10 Eisai R&D Management Co., Ltd. Lyophilized formulation of HGF
DK3192524T3 (da) 2014-09-10 2022-02-14 Kringle Pharma Inc Hgf præparat egnet til behandling af neurologiske lidelser
ES2894477T3 (es) 2016-03-17 2022-02-14 Eisai R&D Man Co Ltd Método para producir factor de crecimiento de hepatocitos (HGF) activo
EP3823677A4 (en) 2018-07-19 2022-06-01 Helixmith Co., Ltd. LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR NAKED DNA GENE THERAPY
US20230022990A1 (en) 2021-05-14 2023-01-26 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58148826A (ja) * 1982-02-26 1983-09-05 Mochida Pharmaceut Co Ltd 糖蛋白質および腫瘍治療剤
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
JPS6410998A (en) * 1986-12-22 1989-01-13 Green Cross Corp Tumor cell inhibitory factor
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPH0741891B2 (ja) * 1987-08-26 1995-05-10 凸版印刷株式会社 容器素材成形装置
FI80741C (fi) * 1987-10-29 1990-07-10 Laennen Tehtaat Oy Modifierat papper.
EP0539590B1 (en) * 1990-07-13 1999-03-31 Snow Brand Milk Products Co., Ltd. Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same

Also Published As

Publication number Publication date
AU5177490A (en) 1990-10-09
KR960009054B1 (ko) 1996-07-10
DE69019962D1 (de) 1995-07-13
JPH0768272B2 (ja) 1995-07-26
IE64005B1 (en) 1995-06-28
HUT58797A (en) 1992-03-30
DE69019962T2 (de) 1995-11-23
US6333309B1 (en) 2001-12-25
EP0462277A1 (en) 1991-12-27
CA2049017C (en) 1998-10-27
EP0462277A4 (en) 1992-08-12
US5587359A (en) 1996-12-24
CA2049017A1 (en) 1990-09-11
FI102681B1 (fi) 1999-01-29
NO180796C (no) 1997-06-25
AU629314B2 (en) 1992-10-01
RU2113480C1 (ru) 1998-06-20
DK0462277T3 (da) 1995-10-30
NO180796B (no) 1997-03-17
NZ232813A (en) 1992-08-26
NO913546D0 (no) 1991-09-09
KR920701256A (ko) 1992-08-11
WO1990010651A1 (en) 1990-09-20
JPH0768272B1 (es) 1995-07-26
NO913546L (no) 1991-11-11
FI102681B (fi) 1999-01-29
ATE123498T1 (de) 1995-06-15
HU902330D0 (en) 1991-12-30
FI914234A0 (fi) 1991-09-09
IE900863L (en) 1990-09-10
RU95110767A (ru) 1997-06-10
HU212513B (en) 1996-07-29
EP0462277B1 (en) 1995-06-07
HU211229A9 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ES2075199T3 (es) Glicoproteina de origen humano; factor activo fisiologicamente que comprende la misma, y preparacion farmaceutica que contiene la misma como ingrediente activo.
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
ES2033259T3 (es) Bases de liberacion controlada de productos farmaceuticos.
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
ES2061684T3 (es) Compuestos de benzoxazina y su uso farmaceutico.
CO4940451A1 (es) Derivados de acido barbiturico con actividad antimetastica y antitumoral
NO173998C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
BG103219A (bg) Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
ES2061688T3 (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
ES2106031T3 (es) Una composicion comprendiendo un factor de crecimiento, su metodo de obtencion y uso.
DE69102704D1 (de) Orales, melatonin enthaltendes arzneimittel.
ES2058343T3 (es) Piridinas disubstituidas.
ES2066390T3 (es) Nuevos derivados del espiro-(4.5)-decano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DK0427124T3 (da) Antacidatabletter
ES2061218T3 (es) Composiciones farmaceuticas estabilizadas.
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ES2150415T3 (es) Peptidos antimicrobianos y resistencia a enfermedades de plantas basadas en ellos.
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
ES2078253T3 (es) Sintetasa de la sustancia ron biologicamente activa y su uso para producir sustancia ron biologicamente activa.
ES2057528T3 (es) Pdgf-a, pdgf-aa, pdgf-ab, procedimientos de preparacion y medicamentos que los contienen.
MX9304133A (es) Nuevos derivados de los fosfolipidos.
ES2151891T3 (es) Derivados de ciclohexano sustituidos con imidazolilo.
ES2188140T3 (es) Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 462277

Country of ref document: ES